Triple drug cocktail targets tough stomach cancer

NCT ID NCT04209686

Ongoing Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study is testing a combination of three drugs—paclitaxel (a chemotherapy), pembrolizumab (an immunotherapy), and olaparib (a targeted therapy)—in 36 adults with advanced gastric or gastroesophageal cancer that has worsened after one prior treatment. The goal is to see if the triple therapy is safe and can improve overall survival. Participants receive the drugs intravenously and by mouth over 21-day cycles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: paclitaxel, pembrolizumab, and olaparib
What this could lead to: If successful, this combination could offer a new treatment option for advanced gastric cancer patients who have run out of standard therapies.
What could go wrong: This is a small, early-phase trial with only 36 participants, so results may not apply broadly. The three-drug combination may cause significant side effects, and it is not yet known if it improves survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED GASTRIC ADENOCARCINOMA

Contacts and locations

Locations

Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, 21231, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.